The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | The outcome of treatment with venetoclax plus HMA in patients with AML with extramedullary disease
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, highlights a study investigating the combination of hypomethylating agents (HMA) with venetoclax for the treatment of acute myeloid leukemia (AML) with extramedullary involvement. The findings revealed that most patients relapsed and needed a transplant, which is not always feasible for elderly patients, making this an unmet clinical need. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The presence of extramedullary involvement in AML has a very bad prognostic impact unfortunately and what we know is that the standard chemotherapy may induce a low rate of response and in the long run also allogeneic stem cell transplantation unfortunately is not able in many cases to eradicate the disease. We have tried to investigate the role of hypomethylating agent and venetoclax in this setting, so in those patients with extramedullary involvement...
The presence of extramedullary involvement in AML has a very bad prognostic impact unfortunately and what we know is that the standard chemotherapy may induce a low rate of response and in the long run also allogeneic stem cell transplantation unfortunately is not able in many cases to eradicate the disease. We have tried to investigate the role of hypomethylating agent and venetoclax in this setting, so in those patients with extramedullary involvement. The CR rate was not so bad but unfortunately at the long run most of these patients relapse and allogeneic stem cell transplantation is mandatory but the problem is that many patients are elderly and so this procedure is not feasible. So I think that at the moment extramedullary AML involvement is still an unmet need and we are still looking for new approaches with a higher efficacy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
